| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/07/2023 | 53.2% | Cantor Fitzgerald | → $160 | Reiterates | Overweight → Overweight |
| 10/24/2023 | 53.2% | Cantor Fitzgerald | → $160 | Initiates Coverage On | → Overweight |
| 10/12/2023 | 53.2% | Citigroup | → $160 | Initiates Coverage On | → Buy |
| 09/07/2023 | 47.45% | Berenberg | → $154 | Initiates Coverage On | → Buy |
| 08/08/2023 | 46.5% | Chardan Capital | $148 → $153 | Maintains | Buy |
| 08/07/2023 | 33.09% | HC Wainwright & Co. | → $139 | Reiterates | Buy → Buy |
| 07/27/2023 | 33.09% | HC Wainwright & Co. | → $139 | Reiterates | Buy → Buy |
| 07/03/2023 | 33.09% | HC Wainwright & Co. | → $139 | Reiterates | → Buy |
| 05/25/2023 | 34.05% | B of A Securities | $118 → $140 | Maintains | Buy |
| 05/24/2023 | 38.84% | Stifel | $102 → $145 | Maintains | Buy |
| 05/22/2023 | 24.47% | Guggenheim | $101 → $130 | Maintains | Buy |
| 05/22/2023 | 48.41% | Goldman Sachs | $135 → $155 | Maintains | Buy |
| 05/22/2023 | 41.71% | Chardan Capital | $133 → $148 | Maintains | Buy |
| 05/22/2023 | 33.09% | HC Wainwright & Co. | $119 → $139 | Maintains | Buy |
| 05/22/2023 | 12.98% | B of A Securities | $105 → $118 | Maintains | Buy |
| 05/07/2023 | 29.26% | Goldman Sachs | → $135 | Maintains | Buy |
| 04/18/2023 | -2.34% | Stifel | → $102 | Initiates Coverage On | → Buy |
| 02/28/2023 | -3.29% | Guggenheim | → $101 | Reiterates | → Buy |
| 02/28/2023 | 13.94% | HC Wainwright & Co. | → $119 | Reiterates | → Buy |
| 02/28/2023 | 18.73% | Goldman Sachs | $79 → $124 | Upgrades | Neutral → Buy |
| 02/28/2023 | 27.35% | Chardan Capital | → $133 | Reiterates | → Buy |
| 11/08/2022 | 27.35% | Chardan Capital | $130 → $133 | Maintains | Buy |
| 11/07/2022 | -24.36% | Goldman Sachs | $74 → $79 | Maintains | Neutral |
| 11/07/2022 | 13.94% | HC Wainwright & Co. | $107 → $119 | Maintains | Buy |
| 08/25/2022 | -29.15% | Goldman Sachs | → $74 | Downgrades | Buy → Neutral |
| 08/09/2022 | 24.47% | Chardan Capital | $137 → $130 | Maintains | Buy |
| 08/08/2022 | -29.15% | Goldman Sachs | $78 → $74 | Maintains | Buy |
| 05/24/2022 | -25.32% | Goldman Sachs | $91 → $78 | Maintains | Buy |
| 03/01/2022 | -10.95% | Goldman Sachs | $125 → $93 | Maintains | Buy |
| 02/28/2022 | 2.45% | HC Wainwright & Co. | $124 → $107 | Maintains | Buy |
| 01/18/2022 | 5.32% | B of A Securities | → $110 | Initiates Coverage On | → Buy |
| 11/30/2021 | 18.73% | HC Wainwright & Co. | $103 → $124 | Maintains | Buy |
| 11/29/2021 | 19.69% | Goldman Sachs | $85 → $125 | Maintains | Buy |
| 11/29/2021 | 18.73% | HC Wainwright & Co. | $103 → $124 | Maintains | Buy |
| 08/09/2021 | -16.7% | Goldman Sachs | $90 → $87 | Maintains | Buy |
| 07/20/2021 | -13.83% | Goldman Sachs | $73 → $90 | Upgrades | Neutral → Buy |
| 05/10/2021 | -30.1% | Goldman Sachs | $85 → $73 | Maintains | Neutral |
| 03/01/2021 | -1.38% | HC Wainwright & Co. | $84 → $103 | Maintains | Buy |
| 02/09/2021 | -7.12% | JonesTrading | → $97 | Initiates Coverage On | → Buy |
| 01/08/2021 | -19.57% | HC Wainwright & Co. | $68 → $84 | Maintains | Buy |
| 09/18/2020 | -4.25% | B. Riley Securities | → $100 | Initiates Coverage On | → Buy |
| 08/19/2020 | 10.11% | Chardan Capital | $100 → $115 | Maintains | Buy |
| 03/10/2020 | -34.89% | HC Wainwright & Co. | $59 → $68 | Maintains | Buy |
| 09/24/2019 | -42.55% | Goldman Sachs | → $60 | Initiates Coverage On | → Neutral |
| 08/06/2019 | -43.51% | HC Wainwright & Co. | $56 → $59 | Maintains | Buy |
| 06/25/2019 | -30.1% | Guggenheim | $48 → $73 | Reiterates | → Buy |
| 05/30/2019 | — | Guggenheim | Initiates Coverage On | → Buy | |
| 12/12/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform |
What is the target price for Krystal Biotech (KRYS)?
The latest price target for Krystal Biotech (NASDAQ: KRYS) was reported by Cantor Fitzgerald on November 7, 2023. The analyst firm set a price target for $160.00 expecting KRYS to rise to within 12 months (a possible 53.20% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Krystal Biotech (KRYS)?
The latest analyst rating for Krystal Biotech (NASDAQ: KRYS) was provided by Cantor Fitzgerald, and Krystal Biotech reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Krystal Biotech (KRYS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Krystal Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Krystal Biotech was filed on November 7, 2023 so you should expect the next rating to be made available sometime around November 7, 2024.
Is the Analyst Rating Krystal Biotech (KRYS) correct?
While ratings are subjective and will change, the latest Krystal Biotech (KRYS) rating was a reiterated with a price target of $0.00 to $160.00. The current price Krystal Biotech (KRYS) is trading at is $104.44, which is within the analyst's predicted range.